Clinical outcomes of everolimus-eluting bioresorbable scaffolds or everolimus-eluting stents in patients with acute myocardial infarction: two-year results of the randomised ISAR-Absorb MI trial

EuroIntervention. 2022 Mar 18;17(16):1348-1351. doi: 10.4244/EIJ-D-21-00653.

Jens Wiebe^{1

2}, Robert A Byrne^{3

4}, Fernando Alfonso⁵, Michael Maeng⁶, Christian Bradaric⁷, Evgeny Kretov⁸, Javier Cuesta⁵, Constantin Kuna¹, Tareq Ibrahim⁷, Fernando Rivero⁵, Mira Heugl¹, Evald Høj Christiansen⁶, Michael Joner^{1

2}, Heribert Schunkert^{1

2}, Karl-Ludwig Laugwitz^{2

7}, Adnan Kastrati^{1

2}, Salvatore Cassese¹

¹ Deutsches Herzzentrum München, Department of Cardiology, Technische Universität München, Munich, Germany.
² DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany.
³ Cardiovascular Research Institute, Mater Private Hospital, Dublin, Ireland.
⁴ School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
⁵ Cardiac Department, Hospital Universitario de La Princesa Madrid, Madrid, Spain.
⁶ Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
⁷ Clinic and Policlinic Internal Medicine I (Cardiology and Angiology), Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
⁸ E.N. Meshalkin National Medical Research Center, Novosibirsk, Russia.

No abstract available

Publication types